Anti-inflammatory effects of GLP-1 in patients with COVID-19
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
INTRODUCTION: Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 receptor agonist (GLP-1 RA) is awell-known glucose-lowering agent with anti-inflammatory effects. AREAS COVERED: Resources were extracted from the PubMed database, using keywords such as glucagon-like peptide-1, GLP-1 RA, SARS-CoV-2, COVID-19, inflammation, in April2021. In this review, the effects of GLP-1RA in reducing inflammation and modifying risk factors of COVID-19 severe complications are discussed. However, GLP-1 is degraded by DPP-4 with aplasma half-life of about 2-5 minutes, which makes it difficult to measure GLP-1 plasma level in clinical settings. EXPERT OPINION: Since no definitive treatment is available for COVID-19 so far, determining promising targets to design and/or repurpose effective medications is necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, as chronic inflammation is associated with developing insulin resistance, GLP-1RA’s anti-inflammatory capabilities may contribute to their overall glucose-lowering benefits.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [34]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 93 · Cited by 21
Research works printed but not linked: 6
- He XW, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, 48, 456
- Sachdeva S, 2020, SN Compr Clin Med, 6, 1
- Kumar R, 2020, ERJ Open Res, 4
- Akella A, 2013, Indian J Exp Biol, 51, 5
- Patoulias D, 2021, Rev Clin Esp, 27
- Anna R, 2021, Diabetes Care
Metadata
- Authors
- Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N.
- Affiliations
- Universal Scientific Education and Research Network (IR)
- Corresponding author
- Rezaei, Nima
- Venue
- Expert Review of Anti-infective Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08-12
- Volume
- 20
- Issue
- 3
- Pages
- 373-381
- ISSN
- 1478-7210 (ISSN-L)
- 1744-8336
- PMC
- PMC8425436
- OpenAlex
- W3189416067
- Cited by
- 21
- References
- 93
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 2 · 2022: 7 · 2021: 2
- FWCI
- 0.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Expert Review of Anti-infective Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- COVID-19 pandemic, SARS-CoV-2, GLP-1 receptor agonists, anti-inflammatory activity, inflammation, dipeptidyl peptidase IV, drug repurposing, risk factors
- MeSH terms
- SARS-CoV-2, COVID-19 Drug Treatment, Glucagon-Like Peptide-1 Receptor Agonists, Anti-Inflammatory Agents, Humans, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-inflammatory effects of GLP-1 in patients with COVID-19. https://app.cochat.ai/papers/10.1080/14787210.2021.1964955
- The paper
- Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022). Anti-inflammatory effects of GLP-1 in patients with COVID-19. Expert Review of Anti-infective Therapy. https://doi.org/10.1080/14787210.2021.1964955
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.